Is Your DNA Data Safe in Blackstone’s Hands?
By Matthew Ponsford,
Neo.Life
| 01. 28. 2021
We’re beginning to get a picture of the people who might have a goldmine in their genome.
The paradox of treating your own DNA as a commodity is that you’d actually be lucky if you’ve got a rare, poorly understood genetic disease, as those troublesome stretches of DNA may be the most valuable for medical research, explains Dennis Grishin, the cofounder of Nebula Genomics, a California company offering whole genome sequencing. You’d be luckier still if you have genetic patterns that would usually cause you to become ill with a disease like this, and yet appear completely healthy. That’s one variety of in-demand DNA: genomes belonging to people that Grishin calls “natural knockouts,” meaning genetic variations in the disease-associated genes in their genomes somehow save them from falling ill.
“There are people who have ‘broken genes’ and actually should be severely sick. But they are not sick for some reason, and we don’t really understand why,” Grishin says. “So there is some kind of compensatory mechanism going on that prevents people from getting sick.”
Sequencing the genomic data of these...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...